Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Mol Immunol. 2012 Feb 1;50(3):125–133. doi: 10.1016/j.molimm.2011.12.013

Fig. 4. Synthetic TLR2 and TLR4 agonists increase the EAU-inducing activity of the uveitogenic peptide IRBP161-180 in the B10RIII mouse.

Fig. 4

(A) B10RIII mice were immunized with 100 μg of uveitogenic peptide IRBP161-180 emulsified in IFA, CFA, or IFA containing TLR ligands as indicated. All the mice received an additional injection of PTx (200 ng/mouse) on day 0. The photographs show the histopathology of EAU in immunized mice (hematoxylin and eosin, original magnification, x200). (B) The in vivo primed T cells were stimulated with IRBP161-180 in the presence of syngeneic APCs for 5 days under Th17 polarizing conditions and IL-17 levels in the culture supernatant were assessed by ELISA.